ArticleJournal of colloid and interface science2023
Cancer cells inhibition by cationic carbon dots targeting the cellular nucleus.
Article in Journal of colloid and interface science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging-Guided Diagnosis and Therapy.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Carbon dots and DNA: DNA binding mechanisms and their effect on the cell cycle arrest.Journal of advanced research · 2026Article
- Cationic carbon dot-silver nanohybrids with enhanced stability and redox control.Discover nano · 2026Article
- Tutorial: strategies for targeting organelles using nanoparticles.Nature protocols · 2026Review
- Interaction of Carbon Dots with Nucleic Acids Is Driven by Their Surface Charge.Journal of chemical information and modeling · 2026Article
- Optimized hexamine-derived carbonized polymer dots as fluorescent nanoswitches for precision spectral imaging sensing of glucocorticoids.Mikrochimica acta · 2026Article
- Multiple Application Strategies of Carbon Dots in Cancer Treatment: Mechanisms, Progress and Challenges.International journal of nanomedicine · 2026Review
- Carbon dots as a green alternative for preventingEco-Environment & Health · 2025Article
- Effect of temperature on the carbonization process of cationic carbon dots: a physicochemical andRSC advances · 2025Article
- Antibacterial carbon dots.Materials today. Bio · 2025Review
- Polyethylenimine-modified graphene quantum dots promote endothelial cell proliferation.Regenerative biomaterials · 2024Article
- Revolutionizing Cancer Care: Advances in Carbon-Based Materials for Diagnosis and Treatment.Cureus · 2024Review
- Computational Investigation of Interactions between Carbon Nitride Dots and Doxorubicin.Molecules (Basel, Switzerland) · 2023Article
- An Overview on Carbon Quantum Dots Optical and Chemical Features.Molecules (Basel, Switzerland) · 2023Review
- Investigation into Red Emission and Its Applications: Solvatochromic N-Doped Red Emissive Carbon Dots with Solvent Polarity Sensing and Solid-State Fluorescent Nanocomposite Thin Films.Molecules (Basel, Switzerland) · 2023Article
- The role of nanoparticles and nanomaterials in cancer diagnosis and treatment: a comprehensive review.American journal of cancer research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Nucleus targeting is tremendously important in cancer therapy. Cationic carbon dots (CCDs) are potential nanoparticles which might enter cells and penetrate nuclear membranes. Although some CCDs have been investigated in nucleus targeting and applied in nuclear imaging, the CCDs derived from drugs, that are able to target the nucleus, bind with DNA and inhibit the growth of cancer cells have not been reported. In this project, 1, 2, 4, 5-benzenetetramine (Y15, a focal adhesion kinase inhibitor) derived cationic carbon dots (Y15-CDs) were prepared via a hydrothermal approach utilizing Y15, folic acid and 1,2-ethylenediamine as precursors. Based on the structural, optical, and morphologic characterizations, Y15-CDs possess rich amine groups and nitrogen in structure, an excitation-dependent photoluminescence emission, and a small particle size of 2 to 4 nm. The DNA binding experiments conducted through agarose gel electrophoresis, UV-vis absorption, fluorescence emission, and circular dichroism spectroscopies, prove that Y15-CDs might bind with DNA via electrostatic interactions and partially intercalative binding modes. In addition, the cell imaging and cytotoxicity studies in human foreskin fibroblasts (HFF), prostate cancer (PC3) and osteosarcoma cells (U2OS) indicate the nucleus targeting and anticancer abilities of Y15-CDs. Most interestingly, Y15-CDs exhibit a higher cytotoxicity to cancer cells (PC3 and U2OS) than to normal cells (HFF), inferring that Y15-CDs might be potentially applied in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.